Decoy Therapeutics approaches its May 12 quarterly print with short sellers visibly retreating — yet the cost of that retreat is still being paid by anyone remaining on the short side.
The lending market tells a story of dramatic normalization from earlier extremes. Short interest has collapsed by nearly 38% over the past month, falling to just 0.24% of the free float — a level too thin to constitute meaningful short pressure on its own. Yet the cost to borrow remains punishingly high at 75.9% annualized, and it has barely budged from a week ago (up roughly 6%). That combination — almost no shares short, but still very expensive to borrow — points to a borrow pool that has tightened dramatically since March, when CTB was running above 150%. Availability has eased sharply alongside the short interest reduction, with utilization now near 3%, far below the 52-week peak of 96.6%. Plenty of room exists in the lending pool for new shorts to enter — but at a steep price.
The ORTEX short score of 45.5 ranks in the 43rd percentile of the universe and has drifted lower over the past two weeks, consistent with the retreat in short positioning. The EPS surprise factor, however, ranks in the 95th percentile — Decoy has a history of beating estimates — though the estimated net loss of $10.7 million and an EPS forecast of -$12.96 underscore this remains an early-stage biotech burning cash with no revenue line to speak of. Enterprise value is deeply negative at approximately -$7.8 million, reflecting a company where cash on hand likely exceeds its total market capitalization of around $3.2 million. That micro-cap profile limits the institutional base: total reported holders number just ten, with Warberg Asset Management the largest at 0.44% of shares outstanding.
Past earnings reactions at Decoy have been volatile and asymmetric. The April 8 print produced a modest 2.7% gain on the day and a 6.2% five-day follow-through. The March 31 event, however, saw the stock fall 6.5% on the day and extend those losses to -13.5% over five sessions. The most striking move came after the December 2025 event, when the stock surged nearly 30% over five days following a flat initial day reaction — a reminder that for a stock this illiquid, post-event drift can be more significant than the first-day move.
The May 12 print is less a referendum on fundamentals — with no revenue, the numbers are largely irrelevant — and more a test of whether any pipeline or financing update can break the stock out of a YTD decline of more than 26%.
See the live data behind this article on ORTEX.
Open DCOY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
